Literature DB >> 25223964

Prognostic value of metabolic tumor volume as measured by fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in nasopharyngeal carcinoma.

Young-Ho Yoon1, Seok-Hwan Lee, Sung-Lyong Hong, Seong-Jang Kim, Hwan-Jung Roh, Kyu-Sup Cho.   

Abstract

BACKGROUND: The prognostic value of the tumor burden characterized by the metabolic tumor volume (MTV) remains under investigation in nasopharyngeal carcinoma (NPC). The purpose of this study was to evaluate the prognostic value of the maximum standardized uptake value (SUVmax ) and MTV according to metabolic volume threshold as measured by positron emission tomography (PET)/computed tomography (CT), and other clinical factors, in patients with NPC.
METHODS: This study was a retrospective chart review. We evaluated the association of SUVmax , MTV2.5 , MTV3.0 , and other clinical factors with overall survival (OS) using Kaplan-Meier and Cox regression models. (MTV2.5 and MTV3.0 are the volume of hypermetabolic tissue within the regions of gross tumor volumes with a SUV value greater than the threshold values of 2.5 and 3.0, respectively.)
RESULTS: Higher MTV2.5 of 31.45 cm(3) and MTV3.0 of 23.01 cm(3) were associated with an increased risk of death (hazard ratio [HR] = 5.028; p = 0.029), although no significant relationship was found between SUVmax and OS. Interestingly, MTV3.0 was associated with OS in both the differentiated and undifferentiated groups, although MTV2.5 was only associated with OS in the undifferentiated group. Among the clinical parameters, only radiotherapy was associated with longer OS (HR = 12.124; p < 0.001).
CONCLUSION: The MTV and radiotherapy could be prognostic values associated with OS. Particularly, MTV2.5 and MTV3.0 might be valuable metabolic parameters for predicting long-term survival in patients with NPC. Furthermore, MTV3.0 may be more useful because it can be applied irrespective of pathologic subtype.
© 2014 ARS-AAOA, LLC.

Entities:  

Keywords:  computed tomography; nasopharyngeal neoplasms; positron-emission tomography; prognosis; radiotherapy; tumor burden

Mesh:

Substances:

Year:  2014        PMID: 25223964     DOI: 10.1002/alr.21363

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  6 in total

1.  18F-FLT and 18F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results.

Authors:  Shi Qi; Yang Zhongyi; Zhang Yingjian; Hu Chaosu
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

2.  Prognostic value of nodal SUVmax of 18F-FDG PET/CT in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

Authors:  So Jung Lee; Chul-Seoung Kay; Yeon-Sil Kim; Seok Hyun Son; Myungsoo Kim; Sea-Won Lee; Hye Jin Kang
Journal:  Radiat Oncol J       Date:  2017-12-15

Review 3.  Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients.

Authors:  Yecai Huang; Mei Feng; Qiao He; Jun Yin; Peng Xu; Qinghua Jiang; Jinyi Lang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

Review 4.  Prognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.

Authors:  Jie Lin; Guozhu Xie; Guixiang Liao; Baiyao Wang; Miaohong Yan; Hui Li; Yawei Yuan
Journal:  Oncotarget       Date:  2017-05-16

Review 5.  What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis.

Authors:  Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-09       Impact factor: 9.236

6.  Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer.

Authors:  Markus Kroenke; Kenji Hirata; Andrei Gafita; Shiro Watanabe; Shozo Okamoto; Keiichi Magota; Tohru Shiga; Yuji Kuge; Nagara Tamaki
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.